Abstract:Introduction: Destruction of cancer stem cells (CSC) is a major therapeutic goal. LGR5 marks active stem cells in many types of solid cancers. It has been very difficult to isolate good antibodies to native LGR5 and attempts to develop ADCs targeting LGR5 have not advanced. We took the alternative approach of using a natural LGR5 ligand to target monomethylauristatin (MMAE) to LGR5-expressing CSC. An Fc domain was fused to the LGR binding domains of RSPO1 and the sortase reaction was used to conjugate a Gly3-val/cit-PAB-MMAE linker at the C-terminal end to create FcF2-MMAE. We previously reported its efficacy in ovarian models here document its activity in other aggressive cancer models. Methods: FcF2-MMAE was produced by transient transfection in HEK293E cells and purified by a sequential Ni-NTA and ion exchange chromatography. OVCAR8 ovarian cancer cells were molecularly engineered to stably express an empty vector (OVCAR8/EV) or LGR5 (OVCAR8/LGR5.6) at a 10-fold higher level. The sortase A enzyme was produced in E. coli. Flow cytometry was used to quantify cell surface LGR5 in live cells using an anti-LGR5 antibody. Results: DEPMAP tools were used to identify cell types with high levels of WNT signaling that drives expression of LGR5. FCM confirmed LGR5 expression in colon LoVo, gastric AGS and neuroblastoma SKNAS cells. All three lines were very sensitive to FcF2-MMAE; GI50 values in 2D cultures were: LoVo 4.5, AGS 0.7 and SKNAS 8.6 nM. IC50 values for stem cell-derived spheroids grown from these lines were: 11.0, 3.0 and 1.70 nM, respectively. The MTD of FcF2-MMAE was found to be >1.5 nmol/g in mice. The plasma half-life was 29.7 h. A q7dx4 IP dose schedule was found to be more effective than a q4dx4 IP schedule. FcF2-MMAE inhibited in vivo SC growth in all 3 models at a dose of 1 nmol/g q7dx4, producing cures in a fraction of AGS tumors and delaying SKNAS growth >2-fold in the absence adverse events. In addition to MMAE, we showed that FcF2-His could be conjugated to the either deruxtecan or PNU159682; FcF2-His loaded with either one of these cytotoxins had low nM or sub nM cytotoxicity and retained the same high selectivity of FcF2-MMAE when tested in isogenic OVCAR8/EV and OVCAR8/LGR5 cells. Conclusions: FcF2-MMAE has activity in xenograft models of very aggressive tumors driven by high levels of WNT signaling (LoVo, AGS, and SKNAS) and LGR5 expression. Efficacy was obtained at doses well below its MTD indicating a wide therapeutic window. The FcF2 core accommodates multiple types of warheads without loss of targeting selectivity. The ability to switch out one cytotoxin for another provides versatility in targeting different diseases. FcF2-MMAE has advantages over ASCs. Its small size relative to antibodies favors better tumor penetration. The binding domains of RSPO1 also target stem cells expressing LGR4 and LGR6 as well as LGR5, something that cannot be achieved with an ADC. These features support the further development of FcF2-MMAE as a stem cell-targeted therapeutic. Citation Format: Maria Carmen Mulero, Catherine Rice, Sukshala A. Jahdav, Willie Pi, Alexander Lin, Mindy Nguyen, Owen Tai, Stephen B. Howell. Therapeutic targeting of LGR5-positive cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3901.

Drug Conjugates of Antagonistic RSPO4 Mutant For Simultaneous Targeting of LGR4/5/6 for Cancer Treatment

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.

Therapeutic Efficacy of a Novel Humanized Antibody-Drug Conjugate Recognizing Plexin-Semaphorin-integrin Domain in the RON Receptor for Targeted Cancer Therapy.

Development of A Novel RON Targeted Antibody‐Drug Conjugates Using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer

Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

Development Of A Novel Ron Receptor Targeted Antibody-Drug Conjugates Using Cysteine Bridging Technology For Potential Treatment Of Pancreatic Cancer

Abstract 3901: Therapeutic targeting of LGR5-positive cancer stem cells

Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Anti‐Pan‐Rspo Chimeric Protein‐Conjugated Albumin Nanoparticle Provides Promising Opportunities in Cancer Targeted Therapy

Preclinical Evaluation Of Anti-Ron Antibody-Drug Maytansinoid Conjugates (Anti-Ron Adc) For Targeted Colorectal Cacner Therapy.

RON Receptor Tyrosine Kinase As a Target for Delivery of Chemodrugs by Antibody Directed Pathway for Cancer Cell Cytotoxicity.

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Targeting RON Receptor Tyrosine Kinase for Treatment of Advanced Solid Cancers: Antibody–drug Conjugates As Lead Drug Candidates for Clinical Trials

Abstract 6328: GPR56 as a therapeutic target for the development of antibody-drug conjugates for the treatment of colorectal cancer

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity

Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors

Sustained Expression Of The Ron Receptor Tyrosine Kinase By Pancreatic Cancer Stem Cells As A Potential Targeting Moiety For Antibody-Directed Chemotherapeutics

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4

Self-Reinforced Cancer Targeting (SRCT) Depending on Reciprocally Enhancing Feedback between Targeting and Therapy

793 Treatment of Anti-Sirpα in Combination with Anti-Taa Exerts Superior Anti-Tumor Activity

Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance